Qurin Diagnostics

Qurin Diagnostics is an early-stage biotech developing a novel platform to improve the accuracy and usability of liquid biopsy for early cancer detection. Its core innovation is a patented sample collection and biomarker pre-concentration technology designed to amplify cancer signals from biofluids like urine, addressing key limitations of current tests. Initially targeting bladder cancer, the company aims to build a pipeline of highly accurate, user-friendly diagnostic tests that facilitate earlier treatment and reduce healthcare costs. Qurin operates as a private, pre-revenue company within the vibrant Leiden Bio Science Park ecosystem.

Patented platform for non-invasive sample collection, biomarker extraction, and pre-concentration. It amplifies cancer signals from biofluids (e.g., urine) to improve sensitivity for early detection and is designed for patient usability and lab automation.

Qurin competes in the liquid biopsy and early cancer detection space, which includes large diagnostic firms (e.g., Roche, Guardant Health, Exact Sciences) and numerous startups. Its primary differentiation is its focus on the pre-analytical sample collection and concentration step to improve signal strength, rather than solely on biomarker discovery or sequencing technology.